Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

chevron_leftPreviosly
Lice feel the itch over Hatchtech deal
01 November 2013

You may also like

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

07 April 2017

Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy

16 March 2020

OneVentures invests in international software company Phocas, bringing business back to Australia and positioning the company for international expansion

18 July 2016

DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

14 October 2021

Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor
clear Close